This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Sandbox Reserved 1227
From Proteopedia
| This Sandbox is Reserved from Jan 17 through June 31, 2017 for use in the course Biochemistry II taught by Jason Telford at the Maryville University, St. Louis, USA. This reservation includes Sandbox Reserved 1225 through Sandbox Reserved 1244. |
To get started:
More help: Help:Editing |
MDM2
| |||||||||||
References
- ↑ Wang, P., Wang, M., Li, S., Ma, L., Xi, S., & He, J. (2016). Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis. Disease Markers, 20164585484.
- ↑ Wang, P., Wang, M., Li, S., Ma, L., Xi, S., & He, J. (2016). Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis. Disease Markers, 20164585484.
- ↑ Trino, S., De Luca, L., Laurenzana, I., Caivano, A., Del Vecchio, L., Martinelli, G., & Musto, P. (2016). P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. Frontiers in Pharmacology, 7, 491. http://doi.org/10.3389/fphar.2016.00491.
- ↑ Ciemny, M. P., Debinski, A., Paczkowska, M., Kolinski, A., Kurcinski, M., & Kmiecik, S. (2016). Protein-peptide molecular docking with large-scale conformational changes: the p53-MDM2 interaction. Scientific Reports, 6, 37532. http://doi.org/10.1038/srep37532.
